Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

583 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Moore KN, et al. Among authors: harter p. Gynecol Oncol. 2024 Oct 25;191:249-258. doi: 10.1016/j.ygyno.2024.10.013. Online ahead of print. Gynecol Oncol. 2024. PMID: 39461270
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.
Perez-Fidalgo A, Schmalfeldt B, George A, Gourley C, Pignata S, Lorusso D, Barretina-Ginesta MP, Romero I, Grimm C, Van Gorp T, Rossing M, Collins DC, Fernebro J, Bjørge L, Leary A, de la Motte Rouge T, Harter P, Kurzeder C, Savva-Bordalo J, You B. Perez-Fidalgo A, et al. Among authors: harter p. Int J Gynecol Cancer. 2024 Oct 23:ijgc-2024-005497. doi: 10.1136/ijgc-2024-005497. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39448084
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.
Haggstrom L, Lee YC, Scott C, Harter P, Woelber L, Ledermann J, Gourley C, McNeish IA, Amant F, Ray-Coquard I, Leary A, Oza AM, Tinker A, González Martin A, Cecere SC, Pignata S, Colombo N, Yoshida H, Marth C, Rosengarten O, Moore KN, Gómez-García EM, Tan D, Friedlander ML. Haggstrom L, et al. Among authors: harter p. Int J Gynecol Cancer. 2024 Oct 22:ijgc-2024-005976. doi: 10.1136/ijgc-2024-005976. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39438068
Dual MAPK Inhibition Triggers Pro-inflammatory Signals and Sensitizes BRAF V600E Glioma to T Cell-Mediated Checkpoint Therapy.
Xing YL, Grossauer S, Park JW, Nasajpour E, Bui B, Morales D, Panovska D, Nirschl JJ, Feng ZP, Wei R, Koeck K, Thomason W, Xiu J, Harter PN, Filipski K, Mahaney K, Ji X, Mulcahy Levy JM, Grant GA, Prolo LM, Walsh KM, Lim M, Hambardzumyan D, Petritsch CK. Xing YL, et al. Among authors: harter pn. bioRxiv [Preprint]. 2024 Oct 7:2023.02.03.526065. doi: 10.1101/2023.02.03.526065. bioRxiv. 2024. PMID: 39416185 Free PMC article. Preprint.
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O'Malley DM, Oaknin A, Thaker P, Oza AM, Colombo N, Gershenson D, Aghajanian CA, Choi CH, Lee YC, Mirza MR, Coleman RL, Cobb L, Harter P, Lustgarten S, Youssoufian H, Banerjee S. Grisham R, et al. Among authors: harter p. Int J Gynecol Cancer. 2024 Oct 7:ijgc-2024-005919. doi: 10.1136/ijgc-2024-005919. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39375168
PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.
Blobner J, Dengler L, Eberle C, Herold JJ, Xu T, Beck A, Mühlbauer A, Müller KJ, Teske N, Karschnia P, van den Heuvel D, Schallerer F, Ishikawa-Ankerhold H, Thon N, Tonn JC, Subklewe M, Kobold S, Harter PN, Buchholz VR, von Baumgarten L. Blobner J, et al. Among authors: harter pn. Cancer Immunol Immunother. 2024 Oct 3;73(12):255. doi: 10.1007/s00262-024-03837-9. Cancer Immunol Immunother. 2024. PMID: 39358663 Free PMC article.
DNA Methylation Profiling of Salivary Gland Tumors Supports and Expands Conventional Classification.
Jurmeister P, Leitheiser M, Arnold A, Capilla EP, Mochmann LH, Zhdanovic Y, Schleich K, Jung N, Chimal EC, Jung A, Kumbrink J, Harter P, Prenißl N, Elezkurtaj S, Brcic L, Deigendesch N, Frank S, Hench J, Försch S, Breimer G, van Engen van Grunsven I, Lassche G, van Herpen C, Zhou F, Snuderl M, Agaimy A, Müller KR, von Deimling A, Capper D, Klauschen F, Ihrler S. Jurmeister P, et al. Among authors: harter p. Mod Pathol. 2024 Sep 25;37(12):100625. doi: 10.1016/j.modpat.2024.100625. Online ahead of print. Mod Pathol. 2024. PMID: 39332710 Free article.
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators.
Denschlag D, Heitz F, Pfisterer J, Tutschkow D, Reuss A, Meier W, Harter P, Wimberger P, Mirza MR, Ray-Coquard I, Scambia G, Kim JW, Colombo N, Oaknin A, Sehouli J, Lindemann K, Lebreton C, Eichbaum M, Spiegelberg S, Woopen H, du Bois A. Denschlag D, et al. Among authors: harter p. Int J Gynecol Cancer. 2024 Sep 25:ijgc-2024-005663. doi: 10.1136/ijgc-2024-005663. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39322609
Determinants of long-term survival in patients with IDH-mutant gliomas.
Katzendobler S, Niedermeyer S, Blobner J, Trumm C, Harter PN, von Baumgarten L, Stoecklein VM, Tonn JC, Weller M, Thon N, Weller J. Katzendobler S, et al. Among authors: harter pn. J Neurooncol. 2024 Sep 24. doi: 10.1007/s11060-024-04826-9. Online ahead of print. J Neurooncol. 2024. PMID: 39316316
583 results